Adverse reactions occurring more often than in single cases are listed according to the following gradation: very often (≥ 10%); often (≥ 1%, <10%); infrequently (≥0.1%, <1%); rarely (≥ 0.01%, <0.1%); very rarely (<0.01%).
Disorders from the blood and lymphatic system: very often - anemia, leukopenia and thrombocytopenia; often - febrile neutropenia; very rarely - thrombocytosis.
Immune system disorders: very rarely an anaphylactic reaction.
Disorders from the metabolism and nutrition: often - anorexia.
Disturbances from the nervous system: often - headache, insomnia, drowsiness; infrequently - impaired cerebral circulation; very rarely - a syndrome of reversible posterior encephalopathy.
Heart Disease: infrequently - heart failure; arrhythmia, predominantly supraventricular; rarely - myocardial infarction.
Vascular disorders: very often - swelling, peripheral edema; rarely - lowering blood pressure, peripheral vasculitis, gangrene; very rarely - the syndrome of increased permeability of capillaries.
Disturbances from the respiratory system: very often - shortness of breath; often - cough, rhinitis; infrequently - bronchospasm, interstitial pneumonitis; rarely - pulmonary edema, adult respiratory distress syndrome.
Disturbances from the gastrointestinal tract system: very often - nausea, vomiting, increased activity of "hepatic" enzymes aspartate aminotransferase (ACT), alanine aminotransferase (ALT) and alkaline phosphatase; often - diarrhea, stomatitis, ulcerative lesions of the oral mucosa, constipation,increased bilirubin concentration; infrequent - severe hepatotoxicity, including hepatic insufficiency, in some cases with a fatal outcome; rarely - increase in the concentration of gamma-glutamyl transferase (GGT); very rarely is ischemic colitis.
Disturbances from the skin and subcutaneous tissues: very often - allergic skin rashes of mild degree, accompanied by itching; alopecia (usually minimal hair loss); often - itching, excessive sweating; rarely - skin ulceration, vesicle formation, peeling, severe skin reactions, including desquamation and bullous skin damage; very rarely - toxic epidermal necrolysis, Stevens-Johnson syndrome.
Disorders from the kidneys and urinary tract: very often - mild proteinuria and hematuria; infrequent - renal insufficiency; rarely - an increase in the concentration of creatinine, urea and lactate dehydrogenase (LDH) in hemolytic-uremic syndrome.
Disturbances from musculoskeletal and connective tissue: often - back pain, myalgia.
Other: aboutChen is often an influenza-like syndrome.
There have also been cases of malaise,sweating; often - fever, asthenia, chills; rarely - reactions at the injection site of a predominantly mild degree.
Hypersensitivity: anaphylactoid reactions were recorded very rarely.
Radiation toxicity was rarely reported (see "Interaction with other types of therapy ").
The use of gemcitabine in combination with paclitaxel in breast cancer
Undesirable phenomena of the third degree of severity
Hematological toxicity: anemia - 5,7%, thrombocytopenia - 5,3%, neutropenia - 31,3%.
Non-hematological toxicity: febrile neutropenia - 4.6%, fatigue - 5.7%, diarrhea - 3.1%, motor neuropathy - 2.3%, sensory neuropathy - 5.3%.
Undesirable phenomena of the IV degree of severity
Hematological toxicity: anemia 1.1%, thrombocytopenia 0.4%, neutropenia 17.2% (grade IV neutropenia lasting more than 7 days was recorded in 12.6% of patients).
Non-hematological toxicity: febrile neutropenia - 0,4%, fatigue - 0,8%, motor neuropathy - 0,4%, sensory neuropathy - 0,4%.
The use of gemcitabine in combination with cisplatin in bladder cancer
Undesirable phenomena of the third degree of severity
Hematological toxicity: Anemia - 24%, thrombocytopenia - 29%.
Non-hematological toxicity: nausea and vomiting - 22%, diarrhea - 3%, infection - 2%, stomatitis - 1%.
Undesirable phenomena of the IV degree of severity
Hematological toxicity: Anemia - 4%, thrombocytopenia - 29%.
Non-hematological toxicity: infection - 1%.
The use of gemcitabine in combination with carboplatin in ovarian cancer
Undesirable phenomena of the third degree of severity
Hematological toxicity: anemia 22.3%, neutropenia 41.7%, thrombocytopenia 30.3%, and leukopenia 48.0%.
Non-hematological toxicity: bleeding - 1.8%, febrile neutropenia - 1.1%.
Undesirable phenomena of the IV degree of severity
Hematological toxicity: anemia - 5,1%, neutropenia - 28,6%, thrombocytopenia - 4,6%, leukopenia - 5,1%.
Non-hematological toxicity: infection without neutropenia - 0,6%.